Claritas Genomics, a leading provider of genetic testing and interpretation services, announces that we have upgraded our laboratory equipment to enhance the accuracy and reliability of DNA sequencing. Our company has invested in the latest state-of-the-art technology, the ILLUMINA HiSeq 2500 sequencing system, which will enable Claritas Genomics to offer exceptionally accurate genetic testing services to clients.
Commenting on the move, Claritas Genomics CEO Patrice Milos said, “As a company, we are excited to add the ILLUMINA HiSeq 2500 sequencing system to our lab. This device will enable us to provide our clients with even more accurate and efficient genetic testing results, positioning our service well for continued growth and success in the years ahead”.
How Does the Equipment Work?
The ILLUMINA HiSeq 2500 sequencing system is an efficient sequencing technology. With its rapid run mode and high output mode, it allows processing and analysis of a limited number of samples and the ability to batch process more extensive studies. The rapid run mode supports long paired-end 150 base pair reads resulting in improved assembly for de novo applications. The high output mode, on the other hand, allows you to batch process more than 6× the samples than rapid mode and complete more significant projects quickly and efficiently.
The newly purchased HiSeq SBS Kits v4 produce 4 billion clusters per run generating up to 1 terabyte (Tb) of data in less than a week. The data generated by HiSeq SBS Kits v4 is of high quality, allowing researchers and clinicians to confidently identify genetic variations that may be present in a patient’s DNA.
The ILLUMINA HiSeq 2500 sequencing system delivers unparalleled accuracy and reliability, of utmost importance when it comes to genetic testing. With superior base call accuracy and low error rates, the HiSeq 2500 system ensures that Claritas Genomics can confidently deliver reliable and accurate results to its customers.
About Our Current Services
Claritas Genomics is a company committed to advancing genomic medicine to improve patient care. The company is currently developing relationships with other top-tier U.S. and international children’s hospitals to create a network of pediatric academic centers that can share data, which is especially important for rare diseases that require vast patient numbers to discover genetic markers. Through leveraging its expertise and resources, Claritas Genomics is well-positioned to make significant contributions to the field of genetic testing and to continue to drive innovation in genomics. Besides genetic testing, we also provide drug testing services for a wide range.
Claritas Genomics is determined to ensure the highest accuracy and quality of service. Thus, the company heavily invests in staff training and hires the most experienced laboratory professionals. The laboratory is CLIA-certified and adheres to all industry standards and regulations.
Claritas Genomics offers genetic testing and interpretation services to healthcare professionals, researchers, and patients worldwide. As a company majority-owned by Boston Children’s Hospital that leverages expertise, assets, and personnel from the hospital’s Genetic Diagnostic Lab, Claritas Genomics is committed to advancing genomic medicine and improving patient care through research, innovation, and high-quality service.
Bottom Line
In summary, Claritas Genomics’ purchase of the ILLUMINA HiSeq 2500 and the featured new HiSeq SBS Kits v4 enzyme system enhances the company’s sequencing abilities and reliability, delivering unparalleled accuracy, and state-of-the-art genetic testing services to clients worldwide. The company remains committed to advancing genomic medicine and improving patient care.
